← ANALYSTS · TIPRANKS
Maury Raycroft · Jefferies
Hits
44%
132 of 303 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+12.0%
Over a year after the rating, TipRanks’ measure
Our companies rated now
20
Buy / hold / sell: 19 / 1 / 0
Upside of the analyst’s targets
+408.9%
Average over 20 current targets, to the last price
The market’s answer to the ratings
+8.6%
Day-0 move against SPY in the rating’s direction, average over 15 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 5on TipRanks 09:55 | KODIWMKodiak Sciences · $5.5B | Reiterated | Buy | $112 | +30.6% | −1.4%next day −2.1% · 5 days +5.4% | ↗ |
| Oct 1on TipRanks 10:25 | QTTBQ32 Bio · $246M | Reiterated | Buy | $29.00 | +285.6% | −0.4%next day −1.0% · 5 days −3.2% | ↗ |
| Sep 28on TipRanks 14:30 | KODIWMKodiak Sciences · $5.5B | Assigned | Buy | $56.00 → $112+100.0% | +30.6% | +178.7%next day +1.5% · 5 days +3.1% | ↗ |
| Sep 28on TipRanks 06:35 | QTTBQ32 Bio · $246M | Initiated | Buy | $29.00 | +285.6% | +6.0%next day +3.4% · 5 days −10.5% | ↗ |
| Sep 10on TipRanks 06:25 | ANLAdlai Nortye Ltd. Sponsored ADR · $701M | Initiated | Buy | $31.00 | +181.1% | +3.3%next day −0.1% · 5 days +0.6% | ↗ |
| Sep 3on TipRanks 09:00 | RAREIWMUltragenyx Pharmaceutical · $1.5B | Reiterated | Buy | $77.00 → $28.00−63.6% | +92.6% | −45.1%next day +3.4% · 5 days −2.6% | ↗ |
| Aug 6on TipRanks Aug 7 03:35 | BDTXIWMBlack Diamond Therapeutics · $100M | Reiterated | Buy | $10.00 | +481.4% | +7.4%next day +1.0% · 5 days +4.0% | ↗ |
| Aug 5on TipRanks 15:20 | TYRAIWMTyra Bioscience · $1.3B | Reiterated | Buy | $44.00 → $42.00−4.5% | +126.8% | −20.8%next day +5.0% · 5 days −1.9% | ↗ |
| Jul 31on TipRanks 10:46 | KPTIIWMKaryopharm Therapeutics · $7M | Reiterated | Buy | $14.00 → $11.00−21.4% | +2,720.5% | −73.3%next day +1.2% · 5 days +6.9% | ↗ |
| Jul 14on TipRanks 16:05 | ERASIWMErasca · $5.2B | Assigned | Buy | $21.00 → $24.00+14.3% | +79.2% | +8.6%next day −10.0% · 5 days −7.3% | ↗ |
| Jul 13on TipRanks 09:12 | COAGIWMHemab Therapeutics Holdings, Inc. · $1.5B | Reiterated | Buy | $39.00 → $47.00+20.5% | +56.3% | +4.7%next day +9.3% · 5 days +26.0% | ↗ |
| Jun 26on TipRanks Jun 25 16:15 | TNGXIWMTango Therapeutics · $3.8B | Upgrade | Buy | $60.00 | +172.2% | +5.1%next day +1.8% · 5 days −7.9% | ↗ |
| Jun 15on TipRanks 10:15 | DNTHIWMDianthus Therapeutics · $4.2B | Reiterated | Buy | $132 | +83.1% | −1.2%next day −3.8% · 5 days +8.6% | ↗ |
| May 12on TipRanks 16:10 | CRBPIWMCorbus Pharmaceuticals · $84M | Reiterated | Buy | $36.00 → $33.00−8.3% | +630.1% | +5.7%next day −2.2% · 5 days −19.8% | ↗ |
| Apr 27on TipRanks 14:10 | CMPXIWMCompass Therapeutics · $158M | Reiterated | Buy | $9.00 | +946.5% | −64.6%next day +3.3% · 5 days +8.0% | ↗ |
| Apr 5on TipRanks Apr 6 07:50 | IDYAIWMIDEAYA Biosciences · $3.3B | Reiterated | Buy | $31.00 → $52.00+67.7% | +58.3% | −1.7%next day −4.5% · 5 days −2.6% | ↗ |
| Feb 25on TipRanks 10:55 | ENGNenGene Holdings · $115M | Reiterated | Buy | $28.00 | +1,576.6% | +2.4%next day −0.1% · 5 days −2.4% | ↗ |
| Dec 8on TipRanks Dec 5 16:20 | RZLTIWMRezolute · $377M | Reiterated | Buy | $15.00 → $20.00+33.3% | +458.7% | −2.1%next day −3.1% · 5 days −83.5% | ↗ |
| Nov 7on TipRanks 06:20 | AUPHIWMAurinia Pharmaceuticals · $2.2B | Upgrade | Buy | $10.00 → $21.00+110.0% | +27.2% | +4.6%next day +0.4% · 5 days +4.9% | ↗ |
| Oct 31on TipRanks Oct 30 19:35 | OPKIWMOpko Health · $1.2B | Downgrade | Hold | $1.60 | +4.6% | −7.2%next day +2.8% · 5 days +0.2% | ↗ |
| Oct 14on TipRanks 15:25 | BCRXIWMBioCryst · $2.0B | Reiterated | Buy | $15.00 | +92.6% | −8.7%next day +5.6% · 5 days +7.4% | ↗ |
| Oct 9on TipRanks 13:05 | BEAMIWMBeam Therapeutics · $2.6B | Initiated | Buy | $41.00 | +74.7% | +3.5%next day −2.9% · 5 days −5.9% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗